期刊文献+

雷那度胺对骨髓间充质干细胞生物学特性及免疫抑制功能的影响

Effects of lenalidomide on biological characteristics and immunosuppressive functions of human bone marrow mesenchymal stem cells
暂未订购
导出
摘要 目的探讨雷那度胺对骨髓间充质干细胞(MSCs)生物学功能和免疫抑制功能的影响。方法将雷那度胺(10μmol/L)加入MSCs中培养,收集细胞检测雷那度胺处理前后MSCs的增殖能力、免疫表型及其对T细胞增殖抑制作用的变化。CCK-8法检测细胞的增殖活力,流式细胞术检测MSCs的增殖周期、免疫表型及其对CD3+T细胞的增殖抑制能力。结果雷那度胺干预不影响MSCs的生长速度、增殖周期和免疫抑制功能;与干预前比较,雷那度胺干预后的MSCs免疫标记有所不同:CD29、CD73的平均荧光强度增高,CD44的平均荧光强度减弱。结论雷那度胺在体外实验中能够影响MSCs表面分子的表达,这可能有助于其在不影响MSCs的生长、增殖和免疫抑制功能的情况下,有效发挥抗肿瘤作用。 Objective To investigate the effects of lenalidomide on the biological and immunosuppressive functions of human bone marrow mesenchymal stem cells (MSCs). Methods MSCs were cultured by lenalidomide of 10 μmol/L and variations of proliferation, phenotype, and inhibition of T-cell proliferation of MSCs before and after being treated by lenalidomide were analyzed. The proliferation rate was detected by the CCK-8 assay. The proliferation cycle, phenotype, and inhibition of CD3 + T-cell proliferation of MSCs were detected by the flow cytometry. Results The growth rate, proliferation, and immunosuppressive functions of MSCs were not affected by the intervention of lenalidomide. Compared with the immunophenotyping of MSCs before being treated by lenalidomide, that of MSCs after being treated by lenalidomide was different. The mean fluorescence intensity (MFI) of CD29 and CD73 increased and the MFI of CD44 decreased. Conclusion Lenalidomide can influence the expression of surface molecules of MSCs in vitro, which may contribute to the antitumor effect without affecting the growth, proliferation, and immunosuppressive functions of MSCs.
出处 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2015年第5期647-652,共6页 Journal of Shanghai Jiao tong University:Medical Science
基金 国家自然科学基金(81170463)~~
关键词 间充质干细胞 雷那度胺 免疫表型 免疫抑制功能 mesenchymal stem cells lenalidomide immunophenotyping immunosuppressive
  • 相关文献

参考文献23

  • 1Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult humart mesenchymal stem cells J ]. Science, 1999, 284 (5411): 143 -147.
  • 2Alakel N, Jing D, Muller K, et al. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133 hematopoietic stem ceils during ex vivo expansion[ J]. Exp Hematol, 2009, 37(4) : 504 -513.
  • 3Jing D, Fonseca AV, Alakel N, et al. Hematopoietic stem cells in coculture with mesenehymal stromal cells-modeling the niche compartments in vitro[ J]. Haematologiea, 2010, 95 (4) : 542 - 550.
  • 4Nautal AJ, Fibbe WE. Immunomodulatory properties of mesenchy- real stromal cells[ J]. Blood, 2007, 110(10) : 3499 - 3506.
  • 5Zhao S, Wehner R, Bornhauser M, et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic conse- quences for immune-mediated disorders[J]. Stem Cells Dev, 2010, 19 (5) : 607 -614.
  • 6List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodys- plastic syndrome with chromosome 5q deletion[ J]. N Engl J Med, 2006, 355(14) : 1456 - 1465.
  • 7Matsuoka A, Toehigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of eytokinesis[ J]. Leukemia, 2010, 24(4) : 748 - 755.
  • 8Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings[J]. Blood Rev, 2010, 24 (suppl 1) : S13 -S19.
  • 9Verhelle D, Corral LG, Wong K, et al, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells [ J ]. Cancer Res, 2007, 67 (2) : 746 - 755.
  • 10Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients [J]. Proc NatlAcadSciU SA, 2007, 104(27): 11406-11411.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部